Welcome to our dedicated page for YS Biopharma Co., Ltd. Warrants SEC filings (Ticker: YSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on YS Biopharma Co., Ltd. Warrants's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into YS Biopharma Co., Ltd. Warrants's regulatory disclosures and financial reporting.
LakeShore Biopharma Co., Ltd. (Nasdaq: LSB / LSBPW) filed its FY 2025 Form 20-F covering the 12 months ended 31 Mar 2025.
- Scale & Structure: 20.77 m ordinary shares outstanding; Cayman-incorporated holding company with substantial PRC operations conducted through wholly-owned subsidiaries such as Beijing Yisheng and Liaoning Yisheng.
- Financials: FY25 net loss of RMB100 m (US$13.9 m), bringing accumulated deficit to US$335 m. Cash on hand RMB107.5 m (US$15 m) versus loans/borrowings of RMB413.9 m (US$57.7 m). Auditor Grant Thornton Zhitong issued a going-concern warning.
- Revenue Mix: 100 % of revenue still derives from its single commercial product, the rabies vaccine YSJA™; pipeline assets (e.g., accelerated-dose PIKA rabies vaccine, PIKA YS-ON-001 immuno-oncology candidate) remain in clinical/pre-clinical stages.
- Key Risks: heavy dependence on one product, intense vaccine competition, sizable cash burn, high leverage, and possible HFCAA-related delisting if PCAOB access lapses. Company faces extensive PRC regulatory, currency-transfer and data-security constraints.
- Regulatory Status: Emerging-growth, non-accelerated filer; U.S. GAAP reporter; no internal-control audit under SOX 404(b).
Overall, the filing underscores liquidity pressure, strategic reliance on rabies franchise, and heightened geopolitical/regulatory headwinds that may impair future financing and market access.
Schedule 13D discloses that Crystal Peak Investment Inc., its parent Crystal Peak Holdings Inc. and sole shareholder/director Huaqin Xue have become controlling shareholders of LakeShore Biopharma Co., Ltd. ("LakeShore"). On 8 Jul 2025 the parties executed a Share & Warrant Purchase Agreement under which Crystal Investment bought 16,987,542 ordinary shares at US$0.883 each (US$15 m cash) and received an equal number of warrants exercisable at US$1.079. All warrants were cashlessly exercised on 11 Jul 2025 for 4,033,790 additional shares, taking the group’s total holding to 21,021,332 shares, or 51.0 % of the 41,212,693 shares outstanding.
The proceeds must be used for operations, expansion of LakeShore’s core business and working-capital needs; any other use requires Crystal Investment’s written consent, giving the new owner de-facto oversight of capital allocation. The acquisition was made for investment purposes, but the filing states the group may buy or sell additional securities depending on price, strategy and market conditions.
The transaction provides immediate liquidity to LakeShore and introduces a single majority owner, signalling potential strategic direction changes, governance realignment and future capital market activity. No criminal or civil proceedings involving the reporting persons were disclosed.
FAQ
What is the current stock price of YS Biopharma Co., Ltd. Warrants (YSBPW)?
